CareDx, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CDNA in the last 30 days.
See all $CDNA insider activity →BTIG raised its price target for CareDx (CDNA) to $81 from $74, citing strong revenue outlook and recent stock performance. The stock has gained 376% over the past year. CareDx reported Q2 2026 earnings of $0.37 per share and revenue of $132 million, both exceeding estimates. The company raised its full-year outlook. Analysts have mixed views on the stock's valuation.
CareDx presented data at ASN Kidney Week 2026 linking elevated AlloSure Kidney dd-cfDNA levels to a nearly 3-fold higher risk of adverse graft outcomes, supporting its use in risk assessment and monitoring.
ARK ETFs sold 670,746 shares of Personalised (PSNL) for $10.7M, bought 254,668 shares of Freenome (FRNM) for $3.1M, sold 59,477 shares of CareDx (CDNA) for $4M, and bought 29,416 shares of Scribe Therapeutics (SCTX) for $609K. These trades indicate ARK's strategic portfolio adjustments.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning CDNA (CareDx, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent CDNA coverage spans financial news, market movers and technology.
Analyst upgrade suggests upside potential.
Positive clinical data may boost AlloSure adoption and CareDx valuation.
Downward pressure expected from the continued sell‑off.
May weigh on the stock briefly.
Positive earnings beat and upgraded guidance likely support further upside.
AlphAI scores every news story that mentions CDNA with an AI model for sentiment and relevance, and aggregates insider trades from CareDx, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BTIG raised its price target for CareDx (CDNA) to $81 from $74, citing strong revenue outlook and recent stock performance. The stock has gained 376% over the past year. CareDx reported Q2 2026 earnings of $0.37 per share and revenue of $132 million, both exceeding estimates. The company raised its full-year outlook. Analysts have mixed views on the stock's valuation.
1 min readCareDx presented data at ASN Kidney Week 2026 linking elevated AlloSure Kidney dd-cfDNA levels to a nearly 3-fold higher risk of adverse graft outcomes, supporting its use in risk assessment and monitoring.
1 min readARK ETFs sold 670,746 shares of Personalised (PSNL) for $10.7M, bought 254,668 shares of Freenome (FRNM) for $3.1M, sold 59,477 shares of CareDx (CDNA) for $4M, and bought 29,416 shares of Scribe Therapeutics (SCTX) for $609K. These trades indicate ARK's strategic portfolio adjustments.
1 min readARK ETFs bought CoreWeave (CRWV) and Kratos (KTOS) for $19.68M and $9.15M, respectively, and sold Robinhood (HOOD) and Personalis (PSNL) for $17.01M and $12.01M. Other trades included Teradyne (TER), Recursion (RXRX), and smaller positions in several other companies.
2 min readCareDx (CDNA), AVITA Medical (RCEL), Azenta (AZTA), and Hinge Health (HNGE) reached 52-week highs on October 2, 2026. CDNA reported $132M Q2 revenue, up 52% YoY. RCEL saw 18% Q2 revenue growth. AZTA reported 12% Q3 revenue growth. HNGE saw 53% Q2 revenue growth and acquired Cylinder Health for $105M.
2 min readKodiak Sciences (KOD) rose 3% to $104 after positive Phase 3 trial results. 908 Devices (MASS) hit $12.93 with Q2 revenue up 23%. Orchestra BioMed (OBIO) reached $6.20, expanding Q2 loss by 23%. CareDx (CDNA) hit a 52-week high with Q2 revenue up 52%. PMV Pharmaceuticals (PMVP) rose 4% to $1.91 on positive clinical data.
2 min readSeveral biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.
2 min readCareDx (CDNA) shares rose 13% to $61.37 on high volume, following a price target increase to $74 by BTIG. Q2 2026 revenue grew 52% YoY, with testing services up 61%. Q3 earnings are expected at $0.24 per share, down 14.3% YoY, and revenue at $122.35M, up 22.3% YoY. The stock has a Zacks Rank of #2 (Buy). Charles River Laboratories (CRL), another medical services company, closed up 6.2% at $294.44, with a Zacks Rank of #2 (Buy).
2 min readCareDx Inc. shares rose 7.96% to $58.64 after BTIG raised its price target to $74 from $60, citing growth confidence. The firm has increased its target by 64% over seven weeks. CareDx focuses on transplant diagnostics and recently published clinical data supporting its AlloSure Kidney test. The company also completed acquisitions and faced mixed analyst views.
2 min readSeveral biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.
3 min read
